INFLUENCE OF INGARON UPON IMMUNE STATE OF THE PATIENTS WITH ADENOCARCINOMA OF LUNG IN THE COURSE OF ADJUVANT THERAPY

This clinical trial included 63 patients with lung adenocarcinoma who underwent radical surgical resection of the tumor at the Thoracic Surgery Department of Rostov Research Oncological Institute from 2009 to 2011, The patients were randomized in two groups, i.e., 33 patients (52%) of the main group received adjuvant chemoimmunotherapy accomplished with Ingaron, whereas 30 cases (48%) in control group were assigned to receive conventional adjuvant chemotherapy. Adjuvant chemoimmunotherapy was administered according to the following schedule: carboplatinum, AUC = 5 i.v. on day 1; etoposide, 100 mg/m2 i.v. on days 1,3,5; interferon-gamma, 500.000 I.E./m2 i.v. on days 2,4,6. In the patiens undergoing lobectomy, carboplatinum was replaced for cisplatinum 100 mg/m2 i.v. on day 1. Comparative evaluation of the both treatment regimens has shown a correcting effect of Ingaron upon cellular immunity links. The Ingaroncontaining chemoimmunotherapy may contribute to improvement of 3-year event-free survival among lung adenocarcinoma patients by 19 percent (p = 0.06607).